Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
ESMO 2024 preview – Astellas unveils its KRAS degrader
ASP3082 grabs some early attention among degraders set to feature at ESMO.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Lilly takes two shots at the Nectin goal
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
Revolution sees a new pan-KRAS challenger
Pfizer moves to take PF-07934040 into its first clinical trial.
